Sign In
Buy APDN
$5.62
+0 (+0%)
At Close: Jan 05, 2026
Applied DNA Announces 1-For-20 Reverse Stock Split
04:05pm, Monday, 22'nd Apr 2024
STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-f
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
07:01am, Tuesday, 09'th Apr 2024
Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and ne
- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods - - Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea ™ DNA I
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
10:00am, Thursday, 14'th Mar 2024
STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platform
Is Applied DNA Sciences (APDN) Outperforming Other Industrial Products Stocks This Year?
10:46am, Wednesday, 21'st Feb 2024
Here is how Applied DNA Sciences (APDN) and Encore Wire (WIRE) have performed compared to their sector so far this year.
Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript
01:32pm, Friday, 09'th Feb 2024
Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
06:41pm, Thursday, 08'th Feb 2024
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.14 per share a year ago.
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
04:05pm, Thursday, 08'th Feb 2024
- Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Milli
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
01:00pm, Monday, 05'th Feb 2024
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today annou
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:15pm, Friday, 02'nd Feb 2024
STONY BROOK, NY / ACCESSWIRE / February 2, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has closed its previously anno
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:00am, Wednesday, 31'st Jan 2024
STONY BROOK, NY / ACCESSWIRE / January 31, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities pu
- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times - STONY BROOK, NY and NEED
Applied DNA Sciences, Inc. (APDN) Q4 2023 Earnings Call Transcript
03:13pm, Friday, 08'th Dec 2023
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q4 2023 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, Presi
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023
09:55pm, Thursday, 07'th Dec 2023
Applied DNA Sciences (NASDAQ: APDN ) just reported results for the fourth quarter of 2023. Applied DNA Sciences reported earnings per share of -26 cents.
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
08:30am, Tuesday, 05'th Dec 2023
STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today annou
